Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics appointed Michael Quirk, PhD, as Senior Advisor for its sepranolone program, leveraging his 20+ years of CNS drug development experience. Dr. Quirk previously served as Chief Scientific Officer at Sage Therapeutics, where he helped develop the first medicines approved for postpartum depression, and brings deep expertise in neuroactive steroid biology.
Key figures
- Pws prevalence low
- 350000
- Pws prevalence high
- 400000
- Patients treated sepranolone
- 335
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.